Compare COGT & AMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COGT | AMG |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.6B |
| IPO Year | 2018 | 1997 |
| Metric | COGT | AMG |
|---|---|---|
| Price | $39.70 | $329.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $32.08 | ★ $335.20 |
| AVG Volume (30 Days) | ★ 2.2M | 381.9K |
| Earning Date | 02-24-2026 | 02-02-2026 |
| Dividend Yield | N/A | ★ 0.01% |
| EPS Growth | N/A | ★ 6.83 |
| EPS | N/A | ★ 16.71 |
| Revenue | N/A | ★ $2,042,100,000.00 |
| Revenue This Year | N/A | $3.63 |
| Revenue Next Year | N/A | $13.85 |
| P/E Ratio | ★ N/A | $19.63 |
| Revenue Growth | N/A | ★ 1.13 |
| 52 Week Low | $3.72 | $139.22 |
| 52 Week High | $43.73 | $331.73 |
| Indicator | COGT | AMG |
|---|---|---|
| Relative Strength Index (RSI) | 61.99 | 75.30 |
| Support Level | $37.70 | $317.10 |
| Resistance Level | $40.40 | $311.51 |
| Average True Range (ATR) | 1.90 | 7.78 |
| MACD | 0.31 | 1.20 |
| Stochastic Oscillator | 83.19 | 88.35 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Affiliated Managers Group offers investment strategies to investors through its network of affiliates. The firm typically buys a majority interest in small to mid-size boutique asset managers, receiving a fixed percentage of revenue from these firms in return. Affiliates operate independently, with AMG providing strategic, operational, and technology support, as well as global distribution. At the end of June 2025, AMG's affiliate network—which includes firms like Abacus Capital and Pantheon dedicated to private markets (which accounted for 19% of AUM), AQR Capital and Capula Investment Management in liquid alternatives (24%), and Harding Loevner, Tweedy Browne, Parnassus, and Yacktman in equities, multi-asset, and bond strategies (57%)—had $771 billion in managed assets.